NovaBay plans to reinitiate clinical evaluation of Auriclosene for impetigo NovaBay Pharmaceuticals announced that it expects to reinitiate a Phase 2b clinical trial of auriclosene for impetigo in 2014. Knowledge gained from the two previous impetigo studies is expected to lead to the use of an optimized formulation of auriclosene for this upcoming clinical trial. NovaBay will be responsible for the planning and execution of the upcoming trial.
News For NBY From The Last 14 Days
Check below for free stories on NBY the last two weeks.